Investigation of Safety of WS 1442 in Slightly Overweight Subjects With Pilot Assessment of Pharmacodynamic Effects of WS 1442 on Endothelial Function.
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2014
At a glance
- Drugs Crataegus (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Dr. Willmar Schwabe Pharmaceuticals
- 13 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Sep 2010 Planned end date changed from 1 Dec 2009 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 27 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.